A cross-sectional study describing the current status of diagnosis and treatment of uroepithelial cancer in hospitals of different grades in Henan Province
Patients diagnosed with uroepithelial carcinoma attending multiple research center hospitals in Henan Province from January 1, 2023 to December 31, 2023 A questionnaire was used to collect and analyze the treatment patterns of patients with early versus advanced uroepithelial cancer in different levels of hospitals in Henan Province.
Study Type
OBSERVATIONAL
Enrollment
400
Kaifeng City Center Hospital
Kaifeng, Henan, China
Luoyang Renda Hospital
Luoyang, Henan, China
Nanyang City Center Hospital
Nanyang, Henan, China
Describing the diagnosis and treatment patterns of patients with early versus advanced uroepithelial carcinoma in different grades of hospitals in Henan Province
To describe the similarities and differences between the way patients with early and advanced uroepithelial cancer are diagnosed and treated in different levels of hospitals in Henan Province and the current guidelines for uroepithelial cancer.
Time frame: up to the patients enrolled,an average of 1 year
Comparison of differences in diagnosis and treatment patterns between patients with early-stage and advanced uroepithelial carcinoma in county hospitals and different consultation departments of the same hospital in Henan province
The main purpose of this study is to compare the differences between the diagnosis and treatment modalities and guidelines for early and advanced uroepithelial cancer patients in Henan Province in county hospitals. It also compares the differences in treatment modalities between different departments in the same level of hospitals.
Time frame: up to the patients enrolled,an average of 1 year
Describing the pathology as well as genetic testing of patients with uroepithelial carcinoma in different grades of hospitals in Henan province
1. Proportion of different genes/proteins tested in patients with uroepithelial cancer (mutations in FGFR, HER2, HRR, ARID1A and CREBBP, TP53, CDKN2A and PD-L1 expression) 2. Proportion of early and advanced uroepithelial cancer patients with high expression/mutations of different genes and use of targeted therapies
Time frame: up to the patients enrolled,an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Qingfeng County People's Hospital
Puyang, Henan, China
Department of Oncology
Xinxiang, Henan, China
Hui County People's Hospital
Xinxiang, Henan, China
Jun County People's Hospital
Xinxiang, Henan, China
Qi County People's Hospital
Xinxiang, Henan, China
Xinxiang Allied Hospital
Xinxiang, Henan, China
Xinxiang Central Hospital
Xinxiang, Henan, China
...and 1 more locations